Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Zhang
Institutions:
Second Hospital of Tianjin Medical University,
Tianjin Medical University
Observed institutions:
Anhui Medical University,
Nantong University,
Tianjin Medical University General Hospital,
Tianjin Medical University Cancer Institute and Hospital,
Second Hospital of Tianjin Medical University,
Tianjin Medical University
show all 6
ORCID:
0009-0009-6420-9499
Observed ORCID:
0009-0009-6420-9499
OpenAlex ID:
A5109519217
2,3,4′,5‐TETRAHYDROXYSTILBENE‐2‐O‐β‐ d ‐GLUCOSIDE SUPPRESSES MATRIX METALLOPROTEINASE EXPRESSION AND INFLAMMATION IN ATHEROSCLEROTIC RATS
2007
·
Wei Zhang
, Chun‐Hua Wang
, et al.
·
Clinical and Experimental Pharmacology and Physiology
·
47
The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-κB
2020
·
Yizhong Ji
, Xucan Tu
, et al.
·
Cellular Signalling
·
16
Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
·
Clinical Cancer Research
·
12
PDF
Antimony exposure induces bladder cancer metastasis via activation of the SUMOylation-dependent TGF-β/Smad2/3 axis
2025
·
Bocun Yi
, Zongyang Zhao
, et al.
·
Environmental Research
·
6
Thyroid follicular lesions induced by thiazole–Zn feed treatment for one year in Sprague-Dawley rats
2015
·
Honglian Yang
, Qingxi Kong
, et al.
·
Experimental and Toxicologic Pathology
·
3
Data from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S5 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Supplementary Table S3 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S1 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Table S4 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
Supplementary Figure S2 from Phase II Pilot Trial of Tislelizumab plus Low-Dose Nab-Paclitaxel for Extensive Very High–Risk Non–Muscle-Invasive Bladder Cancer
2025
·
Yunkai Qie
, Shiwang Huang
, et al.
PDF
Association between amino-acid metabolisms and cardiovascular disease in adults with type 2 diabetes: a population-based cross-sectional study in China and UK Association between amino-acid and CVDs
2023
·
Jingyang Su
, Peng-Zhe Xie
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
14
Citation count:
84
H-index:
4
I10-index:
3
Year
Topic
Type